Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0KTTFS)
| ADC Name |
XMT-2056
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
XMT-2056
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
HT-19
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
STING agonist
|
Payload Info | ||||
| Payload Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Hydrophilic linker of XMT-2056
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastric cancer | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants have HER2-positive recurrent/metastatic solid tumors with progressive disease, ECOG 0-1, and measurable lesions (RECIST 1.1). Key exclusions: recent immunosuppressive therapy (>10mg/day prednisone), prior STING-targeting treatment, active malignancy within 2 years (except low-risk cases), or untreated CNS metastases (stable/treated cases allowed with criteria).
Click to Show/Hide
|
||||
| Administration Dosage |
XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05514717 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2 | ||||
| Primary Endpoint |
Safety and primary objectives focus on evaluating dose-limiting toxicities (DLTs), determining the maximum tolerated dose (MTD), and assessing adverse events over 15 months (Dose Escalation) and up to 3 years (Dose Expansion). The Objective Response Rate (ORR) is measured per RECIST 1.1 for confirmed responses.
|
||||
| Other Endpoint |
Secondary outcomes include ORR, duration of response (DOR), disease control rate (DCR), and comprehensive pharmacokinetic assessments (Tmax, Cmax, AUC, clearance, half-life, volume of distribution, Ctrough) over 3 years. Immunogenicity is evaluated by measuring antidrug/neutralizing antibodies (ADA/NAb).
|
||||